The DOI matches its Crossref record.
Asparaginase Antibody and Asparaginase Activity in Children With Higher-Risk Acute Lymphoblastic Leukemia: Children??s Cancer Group Study CCG-1961
Abstract
We investigated the anti-asparaginase antibody (Ab) and asparaginase enzymatic activity in the sera of 1,001 patients (CCG-1961) with high-risk acute lymphoblastic leukemia (HR-ALL). Patients received nine doses of native Escherichia coli asparaginase during induction. Half of rapid early responders (RER) were randomly assigned to standard intensity arms and continued to receive native asparaginase. The other RER patients and all slow early responders received 6 or 10 doses of PEG-asparaginase. Serum samples (n = 3,193) were assayed for determination of asparaginase Ab titers and enzymatic activity. Three hundred ninety of 1,001 patients (39%) had no elevation of Ab among multiple evaluations-that is, were Ab-negative (<1.1 over negative control)-and 611 patients (61%) had an elevated Ab titer (>1.1). Among these 611 patients, 447 had no measurable asparaginase activity during therapy. Patients who were Ab-positive but had no clinical allergies continued to receive E. coli asparaginase, the activity of which declined precipitately. No detectable asparaginase activity was found in 81 of 88 Ab-positive patients shortly after asparaginase injections (94% neutralizing Ab). The Ab-positive patients with clinical allergies subsequently were given Erwinase and achieved substantial activity (0.1-0.4 IU/ml). An interim analysis of 280 patients who were followed for 30 months from induction demonstrated that the Ab-positive titers during interim maintenance-1 and in delayed intensification-1 were associated with an increased rate of events. The CCG-1961 treatment schedule was very immunogenic, plausibly due to initially administrated native asparaginase. Anti-asparaginase Ab was associated with undetectable asparaginase activity and may be correlated with adverse outcomes in HR ALL.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Malard, F., & Mohty, M. (2020) · The Lancet · doi:10.1016/s0140-6736(19)33018-1 · Cited by 773
L‐asparaginase treatment in acute lymphoblastic leukemia: A focus on Erwinia asparaginase
Pieters, R., Hunger, S. P., Boos, J., Rizzari, C., Silverman, L., Baruchel, A., Goekbuget, N., Schrappe, M., & Pui, C. (2011) · Cancer · doi:10.1002/cncr.25489 · Cited by 569
Villa, C. H., Anselmo, A. C., Mitragotri, S., & Muzykantov, V. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.02.007 · Cited by 397
L-asparaginase in the treatment of patients with acute lymphoblastic leukemia
Egler, R. A., Ahuja, S. P., & Matloub, Y. (2016) · Journal of Pharmacology and Pharmacotherapeutics · doi:10.4103/0976-500x.184769 · Cited by 334
Asparaginase-associated toxicity in children with acute lymphoblastic leukemia
Hijiya, N., & van der Sluis, I. M. (2016) · Leukemia & Lymphoma · doi:10.3109/10428194.2015.1101098 · Cited by 289
Metadata
- Authors
- Panosyan, E. H., Seibel, N. L., Martin-Aragon, S., Gaynon, P. S., Avramis, I. A., Sather, H., Franklin, J., Nachman, J., Ettinger, L. J., La, M., Steinherz, P., Cohen, L. J., Siegel, S. E., & Avramis, V. I.
- Venue
- Journal of Pediatric Hematology/Oncology
- Published
- 2004-04
- Volume
- 26
- Issue
- 4
- Pages
- 217-226
- ISSN
- 1077-4114 (ISSN-L)
- OpenAlex
- W2053852136
- Cited by
- 236
- References
- 0
- FWCI
- 6.38
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Asparaginase Antibody and Asparaginase Activity in Children With Higher-Risk Acute Lymphoblastic Leukemia: Children??s Cancer Group Study CCG-1961. https://app.cochat.ai/papers/10.1097/00043426-200404000-00002
- The paper
- Panosyan, E. H., Seibel, N. L., Martin-Aragon, S., Gaynon, P. S., Avramis, I. A., Sather, H., Franklin, J., Nachman, J., Ettinger, L. J., La, M., Steinherz, P., Cohen, L. J., Siegel, S. E., & Avramis, V. I. (2004). Asparaginase Antibody and Asparaginase Activity in Children With Higher-Risk Acute Lymphoblastic Leukemia: Children??s Cancer Group Study CCG-1961. Journal of Pediatric Hematology/Oncology. https://doi.org/10.1097/00043426-200404000-00002
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.